Open AccessAdvanced Glycation End-Product Precursor Methylglyoxal May Lead to Development of Alzheimer’s Disease
Author(s) -
Wai Yin Li,
Cheuk Yan Lee,
Kwan Ming Lee,
Ge Zhang,
Aiping Lyu,
Kevin K M Yue
Publication year - 2022
Publication title -
diabetes, metabolic syndrome and obesity
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.853
H-Index - 43
ISSN - 1178-7007
DOI - 10.2147/dmso.s382927
Subject(s) - astrogliosis , methylglyoxal , glycation , advanced glycation end product , morris water navigation task , neuroinflammation , endocrinology , medicine , oxidative stress , in vivo , diabetes mellitus , neurodegeneration , hippocampus , pharmacology , central nervous system , chemistry , biology , disease , biochemistry , microbiology and biotechnology , enzyme
Diabetes mellitus (DM) is characterized by chronic hyperglycemia and diabetic complications. Exacerbated cortical neuronal degeneration was observed in Alzheimer's disease (AD) patients with DM. In fact, DM is now considered a risk factor of AD, as DM-induced activation of stress responses in the central nervous system (CNS) such as oxidative stress and neuroinflammation may lead to various neurodegenerative disorders. Methylglyoxal (MG) is one of the most reactive advanced glycation end-product (AGE) precursors. Abnormal accumulation of MG is observed in the serum of diabetic patients. As MG is reported to promote brain cells impairment in the CNS, and it is found that AGEs are abnormally increased in the brains of AD patients. Therefore, the effect of MG causing subsequent symptoms of AD was investigated.